3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Uveal Melanoma
3
Melanoma
2
Leukemia, Myeloid, Acute
2
Carcinoma, Hepatocellular
2
Sarcoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Ichthyosis, X-Linked
1
HER2 Negative Metastatic Breast Cancer
1
Glioma
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Advanced Solid Cancers
1
Advanced Pancreatic Cancer
1
Interventions
Carboplatin
9
pembrolizumab
8
Paclitaxel
8
Cisplatin
8
Radiotherapy, Intensity-Modulated
6
Magnetic Resonance Spectroscopy
6
Gemcitabine
5
fludarabine
4
Specimen Handling
4
Pemetrexed
4
Nivolumab
4
Cyclophosphamide
4
trebananib
3
osimertinib
3
liposomal doxorubicin
3
Radiotherapy
3
Interleukin-2
3
Fluorouracil
3
Docetaxel
3
DNA
3
volociximab
2
poly ICLC
2
lenvatinib
2
fludarabine phosphate
2
Sorafenib
2
Radiosurgery
2
Midazolam
2
Capecitabine
2
Biopsy
2
Bevacizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Carcinoma
×
ADI PEG20
×
Clear all
NCT02029690
2020-09-25
TRAP
Polaris Group
Phase 1
Terminated
85 enrolled